Overview
Akero Therapeutics develops treatments for non-alcoholic steatohepatitis (NASH), a serious liver disease. Its lead therapy, AKR-001, is designed to treat NASH by lowering liver fat, reducing inflammation, and decreasing fibrosis, while also improving lipoprotein profiles to cut cardiovascular risk. The product works by addressing multiple aspects of liver biology to slow or reverse disease progression, and it moves through clinical trials with the goal of regulatory approval for commercialization. The company earns revenue through research partnerships, licensing deals, and, in the future, product sales. Compared with competitors, Akero emphasizes a holistic, multi-faceted approach to NASH and related metabolic issues and pursues collaborations and licensing to fund development. Its ultimate goal is to bring a approved therapy to patients with NASH and related conditions, helping to reduce liver damage and associated cardiovascular problems.
Work here?Claim your company